Videos

Muhammad Umair Mushtaq, MD, discussed the evolution of TIL therapy in melanoma, focusing on first-line treatment potential and immune fitness.

In this closing segment on advanced renal cell carcinoma, Dr. Ornstein synthesizes key themes from the case discussion, emphasizing how disease biology and clinical presentation guide second-line treatment decisions. He highlights that patients with early progression after frontline therapy represent a higher-risk group that often requires a more aggressive treatment approach.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein introduces a patient with high disease burden who progresses within 8 months of frontline immunotherapy plus VEGF receptor targeted therapy, highlighting a more aggressive disease course. He emphasizes that early progression and limited depth of response raise concern for more refractory disease biology.

Jennifer Effie Amengual, MD, detailed a clinical trial evaluating the dual epigenetic combination of tazemetostat and belinostat to treat T-cell lymphomas.

Characterizing the heterogeneity of the CD44-SPP1 axis could help to identify therapeutic strategies for patients with advanced bladder cancer.

There are reimbursement and infrastructure challenges in oncology care, with the need for systemic changes to provide patients with lifesaving behavioral interventions.

Using T-cell–redirecting therapies in less heavily pretreated populations may be a beneficial space to capitalize on, said Barry Paul, MD.

Results from the CHALLENGE trial showed that activity can reduce cancer recurrence for patients with colorectal, breast, and prostate cancers.

Previous data showed deep MRD-negative responses among patients with pretreated relapsed/refractory multiple myeloma who received cevostamab.

Jennifer A. Ligibel, MD, discussed the complex link between weight loss and cancer risk, exploring data from bariatric surgery and the emerging role of GLP-1s.

In this forward-looking segment on advanced renal cell carcinoma, Dr. Ornstein asks the panel to consider how treatment decisions may evolve if newer combination therapies become available in the second-line setting. He introduces the potential role of lenvatinib combined with belzutifan and asks how this regimen might fit into clinical practice.

In this segment on advanced renal cell carcinoma, Dr. Ornstein asks how clinicians differentiate among VEGF receptor targeted therapies when selecting treatment for patients with slower disease progression after prior immunotherapy. He highlights the perception that different TKIs may vary in both efficacy and toxicity.

Reducing vein-to-vein time and expanding manufacturing capacity represent ongoing challenges to optimizing the use of cellular therapy across indications.

Ralph V. Boccia, MD, FACP, explained how his team utilizes patient monitoring kits to manage CRS and keep patients out of the hospital.

Asfar Azmi, PhD, discusses the tricomplex mechanism of daraxonrasib and its impact on overall survival for patients with pancreatic cancer.

Shikha Gupta, PhD, discussed the mechanistic rationale for combining palbociclib and RMC-5552 in translocation renal cell carcinoma (tRCC).

Isaac Allen, PhD, analyzed how postdiagnostic lifestyle behaviors may affect oncological outcomes, including patient health-seeking behavior influences.

CancerNetwork, AJMC, and Pharmacy Times are producing The Bispecifics Network, where Ralph V. Boccia, MD, FACP, breaks down the importance of this initiative.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a patient with intermediate-risk disease who experienced progression after 14 months of frontline dual immune checkpoint inhibitor therapy. He highlights the importance of interpreting prior treatment response and clinical status when selecting second-line therapy.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a patient who progresses after frontline immunotherapy plus VEGF receptor targeted therapy, with prior tolerability challenges including hand-foot syndrome and diarrhea. He highlights the expanding range of second-line options, including HIF-2α inhibitors.